94 related articles for article (PubMed ID: 16892341)
1. Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation.
Brands M; Ergüden JK; Hashimoto K; Heimbach D; Krahn T; Schröder C; Siegel S; Stasch JP; Tsujishita H; Weigand S; Yoshida NH
ChemMedChem; 2006 Jan; 1(1):96-105. PubMed ID: 16892341
[TBL] [Abstract][Full Text] [Related]
2. Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis.
Brands M; Ergüden JK; Hashimoto K; Heimbach D; Schröder C; Siegel S; Stasch JP; Weigand S
Bioorg Med Chem Lett; 2005 Oct; 15(19):4201-5. PubMed ID: 16085415
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
Wallace EM; Moliterni JA; Moskal MA; Neubert AD; Marcopulos N; Stamford LB; Trapani AJ; Savage P; Chou M; Jeng AY
J Med Chem; 1998 Apr; 41(9):1513-23. PubMed ID: 9554884
[TBL] [Abstract][Full Text] [Related]
4. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
De Lombaert S; Blanchard L; Stamford LB; Tan J; Wallace EM; Satoh Y; Fitt J; Hoyer D; Simonsbergen D; Moliterni J; Marcopoulos N; Savage P; Chou M; Trapani AJ; Jeng AY
J Med Chem; 2000 Feb; 43(3):488-504. PubMed ID: 10669576
[TBL] [Abstract][Full Text] [Related]
5. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
Emoto N; Raharjo SB; Isaka D; Masuda S; Adiarto S; Jeng AY; Yokoyama M
Hypertension; 2005 Jun; 45(6):1145-52. PubMed ID: 15897363
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activity of novel potent endothelin-converting enzyme-1 inhibitors.
Firooznia F; Gude C; Chan K; Fink CA; Qiao Y; Satoh Y; Marcopoulos N; Savage P; Beil ME; Bruseo CW; Trapani AJ; Jeng AY
Bioorg Med Chem Lett; 2001 Feb; 11(3):375-8. PubMed ID: 11212114
[TBL] [Abstract][Full Text] [Related]
7. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
[TBL] [Abstract][Full Text] [Related]
8. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
Trapani AJ; Beil ME; Bruseo CW; Fink CA; Hoyer D; Savage P; Jeng AY
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1.
Fink CA; Moskal M; Firooznia F; Hoyer D; Symonsbergen D; Wei D; Qiao Y; Savage P; Beil ME; Trapani AJ; Jeng AY
Bioorg Med Chem Lett; 2000 Sep; 10(17):2037-9. PubMed ID: 10987444
[TBL] [Abstract][Full Text] [Related]
10. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.
Kukkola PJ; Savage P; Sakane Y; Berry JC; Bilci NA; Ghai RD; Jeng AY
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S65-8. PubMed ID: 8587470
[TBL] [Abstract][Full Text] [Related]
11. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
Lin CL; Winardi W; Jeng AY; Kwan AL
Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
[TBL] [Abstract][Full Text] [Related]
12. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications.
Jeng AY; Mulder P; Kwan AL; Battistini B
Can J Physiol Pharmacol; 2002 May; 80(5):440-9. PubMed ID: 12056551
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of an oral endothelin converting enzyme inhibitor on rat detrusor function after outlet obstruction.
Schröder A; Tajimi M; Matsumoto H; Schröder C; Brands M; Andersson KE
J Urol; 2004 Sep; 172(3):1171-4. PubMed ID: 15311064
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme.
Umekawa K; Hasegawa H; Tsutsumi Y; Sato K; Matsumura Y; Ohashi N
Jpn J Pharmacol; 2000 Sep; 84(1):7-15. PubMed ID: 11043447
[TBL] [Abstract][Full Text] [Related]
15. Novel selective quinazoline inhibitors of endothelin converting enzyme-1.
Ahn K; Sisneros AM; Herman SB; Pan SM; Hupe D; Lee C; Nikam S; Cheng XM; Doherty AM; Schroeder RL; Haleen SJ; Kaw S; Emoto N; Yanagisawa M
Biochem Biophys Res Commun; 1998 Feb; 243(1):184-90. PubMed ID: 9473502
[TBL] [Abstract][Full Text] [Related]
16. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
Roques BP
Pathol Biol (Paris); 1998 Mar; 46(3):191-200. PubMed ID: 9769915
[TBL] [Abstract][Full Text] [Related]
17. In-silico characterization of ECE-1 inhibitors.
Ajay Babu P; Colluru VT; Anaparthy N
Comput Biol Med; 2012 Apr; 42(4):446-57. PubMed ID: 22245098
[TBL] [Abstract][Full Text] [Related]
18. Targeting ACE and ECE with dual acting inhibitors.
Hanessian S; Guesné S; Riber L; Marin J; Benoist A; Mennecier P; Rupin A; Verbeuren TJ; De Nanteuil G
Bioorg Med Chem Lett; 2008 Feb; 18(3):1058-62. PubMed ID: 18160283
[TBL] [Abstract][Full Text] [Related]
19. Effect of endothelin-converting enzyme inhibitors on big endothelin-1 induced contraction in isolated rat basilar artery.
Zimmermann M; Jung CS; Vatter H; Raabe A; Seifert V
Acta Neurochir (Wien); 2002 Nov; 144(11):1213-9. PubMed ID: 12434178
[TBL] [Abstract][Full Text] [Related]
20. Utility of endothelin-converting enzyme inhibitors for the treatment of cardiovascular diseases.
Jeng AY
Curr Opin Investig Drugs; 2003 Sep; 4(9):1076-81. PubMed ID: 14582451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
